Original Article
Post-licensure passive safety surveillance of rotavirus vaccines: Reporting sensitivity for intussusception
Vigilancia pasiva de la seguridad postautorización de las vacunas frente a rotavirus: sensibilidad de la notificación de invaginación intestinal
S. Pérez-Vilara,
, J. Díez-Domingoa, J. Gomar-Fayosb, E. Pastor-Villalbac, M. Sastre-Cantóna, J. Puig-Barberàa
Corresponding author
a Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, FISABIO-Public Health, Valencia, Spain
b Servicio de Ordenación y Control del Medicamento, Dirección General de Farmacia y Productos Sanitarios, Valencia, Spain
c Servicio de Salud Infantil y de la Mujer, Dirección General de Salud Pública, Valencia, Spain
Read
5719
Timeswas read the article
2183
Total PDF
3536
Total HTML
Share statistics
array:24 [ "pii" => "S2341287914000349" "issn" => "23412879" "doi" => "10.1016/j.anpede.2013.10.006" "estado" => "S300" "fechaPublicacion" => "2014-08-01" "aid" => "1440" "copyright" => "Asociación Española de Pediatría" "copyrightAnyo" => "2013" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2014;81:77-85" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2037 "formatos" => array:3 [ "EPUB" => 122 "HTML" => 1453 "PDF" => 462 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1695403313004311" "issn" => "16954033" "doi" => "10.1016/j.anpedi.2013.10.027" "estado" => "S300" "fechaPublicacion" => "2014-08-01" "aid" => "1440" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2014;81:77-85" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2840 "formatos" => array:3 [ "EPUB" => 113 "HTML" => 2254 "PDF" => 473 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Vigilancia pasiva de la seguridad postautorización de las vacunas frente a rotavirus: sensibilidad de la notificación de invaginación intestinal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "77" "paginaFinal" => "85" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Post-licensure passive safety surveillance of rotavirus vaccines: Reporting sensitivity for intussusception" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S. Pérez-Vilar, J. Díez-Domingo, J. Gomar-Fayos, E. Pastor-Villalba, M. Sastre-Cantón, J. Puig-Barberà" "autores" => array:6 [ 0 => array:2 [ "nombre" => "S." "apellidos" => "Pérez-Vilar" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Díez-Domingo" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Gomar-Fayos" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Pastor-Villalba" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Sastre-Cantón" ] 5 => array:2 [ "nombre" => "J." "apellidos" => "Puig-Barberà" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2341287914000349" "doi" => "10.1016/j.anpede.2013.10.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287914000349?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403313004311?idApp=UINPBA00005H" "url" => "/16954033/0000008100000002/v1_201407300107/S1695403313004311/v1_201407300107/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2341287914000489" "issn" => "23412879" "doi" => "10.1016/j.anpede.2013.05.001" "estado" => "S300" "fechaPublicacion" => "2014-08-01" "aid" => "1311" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2014;81:86-91" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2453 "formatos" => array:3 [ "EPUB" => 132 "HTML" => 1908 "PDF" => 413 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Domiciliary parenteral antibiotic therapy: A prospective analysis of the last 12 years" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "86" "paginaFinal" => "91" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento antimicrobiano parenteral domiciliario: análisis prospectivo de los últimos 12 años" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 479 "Ancho" => 1436 "Tamanyo" => 44516 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Age distribution (in bar diagram) of patients who received OPAT.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.J. Peláez Cantero, A. Madrid Rodríguez, A.L. Urda Cardona, A. Jurado Ortiz" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M.J." "apellidos" => "Peláez Cantero" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Madrid Rodríguez" ] 2 => array:2 [ "nombre" => "A.L." "apellidos" => "Urda Cardona" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Jurado Ortiz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403313002361" "doi" => "10.1016/j.anpedi.2013.05.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403313002361?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287914000489?idApp=UINPBA00005H" "url" => "/23412879/0000008100000002/v1_201408130145/S2341287914000489/v1_201408130145/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2341287914000507" "issn" => "23412879" "doi" => "10.1016/j.anpede.2013.10.008" "estado" => "S300" "fechaPublicacion" => "2014-08-01" "aid" => "1435" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2014;81:69-76" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1741 "formatos" => array:3 [ "EPUB" => 127 "HTML" => 1208 "PDF" => 406 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Imported infectious diseases in tertiary hospitals" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "69" "paginaFinal" => "76" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Patología infecciosa importada en hospitales terciarios" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "N. Rius Gordillo, A. Martín Nalda, S. Otero Romero, P. Soler-Palacín, E. Sulleiro Igual, M. Espiau Guarner, A. Fernández-Polo, C. Figueras Nadal" "autores" => array:8 [ 0 => array:2 [ "nombre" => "N." "apellidos" => "Rius Gordillo" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Martín Nalda" ] 2 => array:2 [ "nombre" => "S." "apellidos" => "Otero Romero" ] 3 => array:2 [ "nombre" => "P." "apellidos" => "Soler-Palacín" ] 4 => array:2 [ "nombre" => "E." "apellidos" => "Sulleiro Igual" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Espiau Guarner" ] 6 => array:2 [ "nombre" => "A." "apellidos" => "Fernández-Polo" ] 7 => array:2 [ "nombre" => "C." "apellidos" => "Figueras Nadal" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403313004268" "doi" => "10.1016/j.anpedi.2013.10.022" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403313004268?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287914000507?idApp=UINPBA00005H" "url" => "/23412879/0000008100000002/v1_201408130145/S2341287914000507/v1_201408130145/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Post-licensure passive safety surveillance of rotavirus vaccines: Reporting sensitivity for intussusception" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "77" "paginaFinal" => "85" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "S. Pérez-Vilar, J. Díez-Domingo, J. Gomar-Fayos, E. Pastor-Villalba, M. Sastre-Cantón, J. Puig-Barberà" "autores" => array:6 [ 0 => array:4 [ "nombre" => "S." "apellidos" => "Pérez-Vilar" "email" => array:1 [ 0 => "perez_silvil@gva.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J." "apellidos" => "Díez-Domingo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "J." "apellidos" => "Gomar-Fayos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "E." "apellidos" => "Pastor-Villalba" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:3 [ "nombre" => "M." "apellidos" => "Sastre-Cantón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "J." "apellidos" => "Puig-Barberà" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, FISABIO-Public Health, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Ordenación y Control del Medicamento, Dirección General de Farmacia y Productos Sanitarios, Valencia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Salud Infantil y de la Mujer, Dirección General de Salud Pública, Valencia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vigilancia pasiva de la seguridad postautorización de las vacunas frente a rotavirus: sensibilidad de la notificación de invaginación intestinal" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The first vaccine against rotavirus, Rotashield<span class="elsevierStyleSup">®</span>, was licensed in the United States in 1998, but was withdrawn a few months later<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> once population-based epidemiological studies <a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> had confirmed the concern generated by the reporting of 15 cases of intussusception to the <span class="elsevierStyleItalic">Vaccine Adverse Events Reporting System</span> (VAERS) passive surveillance system after the distribution of 1.8 million doses.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Two new vaccines, both live-attenuated and orally administered, were authorised several years later following various pre-licensure clinical trials designed to exclude this association<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a>: a monovalent human vaccine, Rotarix<span class="elsevierStyleSup">®</span> and a pentavalent human-bovine vaccine, RotaTeq<span class="elsevierStyleSup">®</span>. These vaccines, available in Spain since 2006 and 2007 respectively, were not included in the immunisation schedule, but have been recommended by paediatricians and paid for by parents. In 2010 contamination with a virus was detected in both vaccines and they were recalled from the market.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,8</span></a> Months later, after it was ascertained that this finding did not pose safety or efficacy problems, the distribution of RotaTeq<span class="elsevierStyleSup">®</span> was authorised once again,<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> and the re-release of Rotarix<span class="elsevierStyleSup">®</span> lots is imminent. The summaries of product characteristics of both vaccines recommended starting the vaccination schedule from 6 weeks of age and ending it by 24 weeks (Rotarix<span class="elsevierStyleSup">®</span>) and 26 weeks (RotaTeq<span class="elsevierStyleSup">®</span>) of age. In 2012 the top age limit of the RotaTeq<span class="elsevierStyleSup">®</span> vaccine was raised to 32 weeks.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The clinical trials and post-licensure surveillance have not shown evidence of serious adverse reactions associated to these vaccines,<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a> except for intussusception, an association that has been monitored carefully. Post-licensure studies showed an increased risk following the first dose in Mexico (Rotarix<span class="elsevierStyleSup">®</span>)<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> and Australia (RotaTeq<span class="elsevierStyleSup">®</span>),<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> and following the second dose (Rotarix<span class="elsevierStyleSup">®</span>) in Brazil,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> although it was considerably smaller than the risk observed in association with Rotashield<span class="elsevierStyleSup">®</span>. In the United States, no association between RotaTeq<span class="elsevierStyleSup">®</span> and intussusception was found with the data available from the VAERS<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> passive surveillance system nor the data from early observational studies.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14–17</span></a> However, VAERS data on a larger number of distributed doses suggested the possibility of this association,<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> which has been recently confirmed.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19,20</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In Spain, post-licensure surveillance consists mostly of passive surveillance. However, it is known that underreporting occurs in these systems. Its degree is mostly related to the seriousness of the event, its temporal proximity to vaccination, and awareness of the association and the obligation to report such events.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> On the other hand, reporting can increase in the first years following authorisation of a new drug<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> or be stimulated when the medication is subject to media exposure, either because there is a well-known association or because the regulatory authorities have issued some kind of warning.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> Estimating the amount of under- and overreporting in a passive surveillance system allows for the assessment of the system's validity in detecting adverse events, and consequently its usefulness, but this requires an adequate reference for comparison.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The aims of this study were to describe the reports of suspected adverse reactions to rotavirus vaccines registered by the CFCV (Centro de Farmacovigilancia de la Comunidad Valenciana/Pharmacovigilance Centre of the Autonomous Community of Valencia) and assess reporting sensitivity in this passive surveillance system for a serious and rare event such as intussusception.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Design</span><p id="par0030" class="elsevierStylePara elsevierViewall">Descriptive retrospective study of the reports of suspected adverse events to rotavirus vaccines registered in the database of the Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano (Spanish System for the Surveillance of Medications Used in Humans, SEFV-H) through the CFCV between January 1, 2007 and December 31, 2011.</p><p id="par0035" class="elsevierStylePara elsevierViewall">To compare the rate of reporting intussusception to the CFCV with a baseline reference, we used the data of a retrospective observational study designed to estimate the association between intussusception and the administration of rotavirus vaccines. This study included all confirmed intussusception cases in resident children less than 10 months of age admitted to public hospitals of the Autonomous Community of Valencia during the same period.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Both studies were authorised by the Clinical Research Ethics Board of the Dirección General de Salud Pública-Centro Superior de Investigación en Salud Pública.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Data sources</span><p id="par0045" class="elsevierStylePara elsevierViewall">In Spain, suspected adverse effects are reported through the Programa de Notificación Espontánea de Reacciones Adversas a Medicamentos (Programme of Spontaneous Reporting of Adverse Reactions to Medication). Health professionals, manufacturers, and since 2013 citizens, too,<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> report suspected reactions to the corresponding pharmacovigilance centre of their autonomous community.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> The CFCV receives the reports, analyses them, encodes them, and enters them in the database of the Drug Adverse Event Manager of the Information System for the Control and Regulation of Drugs and Health Products, which records them electronically in FEDRA, the database of the SEFV-H.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">The vaccine doses administered in public and private health centres of the Autonomous Community of Valencia are registered in the SIV (Vaccine Information System). This system also allows health professionals to perform reports of suspected adverse reactions to vaccines, which are then submitted electronically to the CFCV.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">The Minimum Basic Data Set (CMBD) is a record of the discharges from hospitals of the National Healthcare System.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> We identified all episodes of intussusception in children younger than 10 months hospitalised during the period under study in this database by searching for the specific IDC-9-CM code (560.0) in any of the diagnostic fields. These cases were reviewed and confirmed using the standardised case definition for intussusception of the Brighton Collaboration (BC)<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). The vaccination status for rotavirus of these patients, and if applicable the vaccination date, were obtained from the SIV. In patients with inconsistent data, vaccination date and the number of doses were confirmed by the parents or legal guardians.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Data analysis</span><p id="par0060" class="elsevierStylePara elsevierViewall">The reported suspected adverse events were described in terms of their severity<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> and of the affected MedDRA system-organ classes.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a> We calculated the latency for each event as the time interval between the onset of symptoms and the vaccination date, and duration as the interval between symptom onset and symptom resolution. We did the descriptive analysis of the data using the statistical software Stata/SE 12 (StataCorp LP, Texas, United States).</p><p id="par0065" class="elsevierStylePara elsevierViewall">The expected frequencies for non-intussusception suspected adverse events described in the summary of product characteristics were calculated using the total number of doses of rotavirus vaccines registered in the SIV as the denominator (December 20, 2012).</p><p id="par0070" class="elsevierStylePara elsevierViewall">We calculated the reporting sensitivity<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> for reports of detected intussusception to the CFCV by dividing the rate of intussusception reporting to the CFCV by the rate of confirmed intussusceptions in children vaccinated against rotavirus (levels 1 or 2 of diagnostic certainty in the BC classification) found in the observational study.</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><p id="par0075" class="elsevierStylePara elsevierViewall">During the 2007–2011 period, at least 185,654 doses of the 2 available rotavirus vaccines were administered in the Autonomous Community of Valencia, and a total of 37 suspected adverse reactions were reported. The reporting rate was 20 per 100,000 administered doses.</p><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Description of reports</span><p id="par0080" class="elsevierStylePara elsevierViewall">There were 3 reports of suspected adverse reactions in 2007, 6 in 2008, 18 in 2009, 5 in 2010, and 5 in 2011. The reporting rates were 17, 14, 34, 18, and 11 per 100,000 administered doses, respectively.</p><p id="par0085" class="elsevierStylePara elsevierViewall">The 37 reports comprised a total of 91 suspected adverse reactions, with a median of 2 events by report, a mean of 2.5 (SD: 2.0), and a range of 1 to 10.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Three reports contained vaccination errors, so we analysed them separately.</p><p id="par0095" class="elsevierStylePara elsevierViewall">In the remaining 34 reports, 65% of the children were male. For the 33 reports that included information on age, the median and mean age were 4 months (SD: 1.7), with a range of 2–10 months of age. In 19 (56%) reports, the rotavirus vaccine was administered simultaneously with other vaccines.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Reports of suspected non-serious adverse reactions</span><p id="par0100" class="elsevierStylePara elsevierViewall">Out of the 34 reports, 25 (74%) were classified as non-serious, and they included 35 suspected adverse reactions. The events most frequently reported were fever (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>16), diarrhoea (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>8; includes diarrhoea and gastroenteritis), and vomiting (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>5). The other reported events were hyperthermia, irritability, abdominal pain, abnormal stools, generalised erythema, and urticaria.</p><p id="par0105" class="elsevierStylePara elsevierViewall">The median latency period corresponded to the vaccination date, with symptoms appearing 3 days post-vaccination at the latest. In the 23 reports that included information for duration, the suspected adverse reactions did not last more than 7 days, with a median duration of 1 day.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Reports of suspected serious adverse reactions</span><p id="par0110" class="elsevierStylePara elsevierViewall">Nine of the 34 reports (26%) were classified as serious, and they included a total of 36 suspected adverse reactions.</p><p id="par0115" class="elsevierStylePara elsevierViewall">The 2 reported cases of intussusception occurred in a 4-month-old girl whose symptoms, which included melenas, hyperhidrosis, and thrombocytopenia, started 6 days after vaccination, and in a 3-month-old boy whose symptoms, with haemorrhagic diarrhoea, started 7 days after vaccination. Both conditions were resolved, although there is no information on the procedures employed in their management.</p><p id="par0120" class="elsevierStylePara elsevierViewall">Other reported events included one case of gastrointestinal disorder accompanied by diarrhoea with mucus and blood in the stool with condition aggravated (specifics were not given); one of loss of consciousness accompanied by hypotonia, apnoea, and foaming at the mouth; one of febrile seizure with decreased mobility; one of bronchospasm accompanied by fever, vomiting, and diarrhoea; one urinary tract infection with fever, abdominal distention, decreased appetite, and aerophagia; and 2 cases of tachycardia, one supraventricular and one unspecified accompanied by fever, irritability, hypotonia, pallor, and vomiting.</p><p id="par0125" class="elsevierStylePara elsevierViewall">In the 7 reports that provided information on the latency period, the median latency was 1 day, with the onset of symptoms occurring between the day of vaccination and the 113 days that followed. Symptom duration in serious events was not greater than 6 days in the 3 reports that offer this information, and the median duration was 5 days.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Frequency of suspected adverse reaction reports by affected MedDRA system organ class</span><p id="par0130" class="elsevierStylePara elsevierViewall">The 34 reports that had to do with the safety of rotavirus vaccines described a total of 71 suspected adverse reactions, of which 27 (38%) corresponded to gastrointestinal disorders and 26 (37%) to general disorders and administration site conditions. The remaining suspected reactions were classified into nervous system disorders, skin and subcutaneous disorders, infections and infestations, respiratory, thoracic, and mediastinal disorders, cardiac disorders, blood and lymphatic system disorders, metabolism and nutrition disorders, vascular disorders, and musculoskeletal and connective tissue disorders (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Observed and expected frequencies by administered doses</span><p id="par0135" class="elsevierStylePara elsevierViewall">The comparison of the observed frequencies of suspected (non-intussusception) adverse reactions described in the summaries of product characteristics, with the expected frequencies based on clinical trials and post-licensure surveillance, shows that in every case in which the comparison could be made, the observed frequencies (based on reports) were much lower than expected (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Sensitivity of the CFCV (Centro de Farmacovigilancia de la Comunidad Valenciana) for the detection of rare and serious adverse events: intussusception</span><p id="par0145" class="elsevierStylePara elsevierViewall">The CFCV received reports of 2 cases of intussusception diagnosed up to 7 days following the administration of a rotavirus vaccine dose. The observational study found that 4 confirmed cases with Level 1 or 2 of diagnostic certainty for the standardised BC case definition of intussusception were detected in the same time period for the same risk window (1–7 days post-vaccination). Consequently, the reporting sensitivity for reports to the CFCV for this risk window was of 50%. The sensitivities for the 1–21, 1–30, and 1–42 days risk windows were 22%, 20%, and 17% respectively (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>).</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Reports of vaccination errors</span><p id="par0150" class="elsevierStylePara elsevierViewall">The 3 reports that described vaccination errors were classified as serious. The 3 cases corresponded to one 6-month-old boy who developed symptoms suggestive of rotavirus infection 75 days after vaccination, one 19-month-old girl who presented these symptoms 435 days after vaccination, and a boy of unknown age who had the onset of symptoms approximately 3 months after vaccination. The available data were not enough to determine whether they had completed the vaccination schedule, or whether the diagnosis was confirmed by laboratory tests.</p></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Discussion</span><p id="par0155" class="elsevierStylePara elsevierViewall">Passive surveillance data from the CFCV after more than 185,000 doses registered in the SIV over a period of 5 years suggest that the available vaccines against rotavirus offer a good safety profile overall, as the most frequently reported suspected adverse reactions were fever, diarrhoea, and vomiting, consistent with the results of the pre-licensure clinical trials. Seventy-four percent of reported events were classified as non-serious, and the observed frequency of reports relative to the number of expected non-intussusception adverse event reports was very low.</p><p id="par0160" class="elsevierStylePara elsevierViewall">Intussusception, reported twice within the first 7 days following vaccination against rotavirus, has been associated with the administration of both vaccines.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11,19</span></a> Since the intestinal replication of the vaccine virus in the 7 days post-vaccination<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> makes it biologically plausible, we must carefully assess this risk in the Autonomous Community of Valencia. We want to highlight that the CFCV has shown a sensitivity of 50% for the detection of intussusception in the first 7 days after vaccination, which is very close to the sensitivity estimated for VAERS while Rotashield<span class="elsevierStyleSup">®</span> was in the market.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">32</span></a> This relatively high reporting sensitivity for intussusception does not necessarily apply to other adverse events, as intussusception is manifested in close temporal proximity to vaccination, and the experience with Rotashield<span class="elsevierStyleSup">®</span>, added to the strict monitoring that the new vaccines have been subject to, contribute to the awareness of a potential association.<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21,32</span></a> Still, it is a relief that there have been no reports of Kawasaki disease after the administration of at least 118,996 RotaTeq<span class="elsevierStyleSup">®</span> doses (SIV, December 20, 2012), as an increase—although not statistically significant—in the rate of this disease was observed during pre-licensure trials.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> This potential association has also not been supported by the passive surveillance through VAERS<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> nor established by one observational study.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">34</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">The detection of serious adverse events by passive surveillance systems can be inaccurate, especially if reports do not provide sufficient information. The reported suspected adverse reactions that had not been described in the summaries of product characteristics were tachycardia, urinary tract infection, and thrombocytopaenia. However, these reports do not suggest that these are new signs that require exhaustive investigation, as in addition to the low reporting rate, supraventricular tachycardia tends to appear in infants younger than 1 year for causes that are not related to vaccination,<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> unspecified tachycardia was accompanied by fever, urinary tract infections are a condition that is not associated with vaccination,<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a> and thrombocytopaenia was described as part of an intussusception report that did not suggest a case of immune thrombocytopaenic purpura (ITP). Furthermore, ITP, while associated with the measles-mumps-rubella vaccine in very low frequencies and very occasionally with other viral vaccines, has not been associated with rotavirus vaccines.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> At any rate, temporal proximity and suspected association with the vaccine are reason enough to report,<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> and it is important that health professionals remember their obligation to report suspected adverse reactions to drugs and vaccines, especially in the cases of serious events.</p><p id="par0170" class="elsevierStylePara elsevierViewall">When it comes to simultaneous administration with other vaccines, it is difficult to attribute the suspected event to a specific vaccine, especially when the disorder has been described in association with more than one of them. Simultaneous administration of Rotarix<span class="elsevierStyleSup">®</span> or RotaTeq<span class="elsevierStyleSup">®</span> with other vaccines, such as combined diphtheria, tetanus toxoid, acellular pertussis vaccine, inactivated poliovirus vaccine, <span class="elsevierStyleItalic">Haemophilus influenzae</span> type b conjugate, hepatitis B vaccine, and pneumococcal conjugate vaccine have been shown not to interfere significantly with the protective immune responses or safety profile of the respective vaccines.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">An important limitation of our study is the lack of information on the brand and the number of administered vaccine doses in pharmacovigilance reports, which makes it impossible to associate suspected adverse events or calculate expected frequencies of events by the brand and number of administered doses of vaccine. However, although the composition of both vaccines is different,<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a> they have a similar mechanism of action,<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> although they seem to differ in the association of intussusception with the number of administered doses.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">The SIV can be accessed from all public and some private centres where vaccines are administered, but since vaccination against rotavirus is not included in the immunisation schedule, the number of doses reported to the SIV may be lower than the number of administered doses. When we compared the number of distributed doses (IMS Health) with the number of doses recorded in the SIV in the 2008–2010 period, we determined that approximately 83% of the distributed vaccines were registered in the SIV as having been administered.</p><p id="par0185" class="elsevierStylePara elsevierViewall">The results of this study suggest that rotavirus vaccines have a good safety profile overall, and that compared to other passive surveillance systems, the CFCV has a high-enough reporting sensitivity to detect signs of a potential association with intussusception. This risk needs to be investigated by means of well-designed epidemiological studies, and weighted against the evident benefits<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6,40</span></a> provided by these vaccines.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Conflicts of interest</span><p id="par0190" class="elsevierStylePara elsevierViewall">JDD, JPB, MSC and SPV work in the Área de Investigación en Vacunas (Department of Vaccine Research) of FISABIO-Public Health. This institution has participated and continues to participate in clinical trials and epidemiological studies funded by GSK, MSD and SP-MSD.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:2 [ "identificador" => "xres360532" "titulo" => array:5 [ 0 => "Abstract" 1 => "Introduction" 2 => "Materials and methods" 3 => "Results" 4 => "Conclusions" ] ] 1 => array:2 [ "identificador" => "xpalclavsec340394" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres360531" "titulo" => array:5 [ 0 => "Resumen" 1 => "Introducción" 2 => "Material y métodos" 3 => "Resultados" 4 => "Conclusiones" ] ] 3 => array:2 [ "identificador" => "xpalclavsec340395" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Materials and methods" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Design" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Data sources" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Data analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0030" "titulo" => "Results" "secciones" => array:7 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Description of reports" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Reports of suspected non-serious adverse reactions" ] 2 => array:2 [ "identificador" => "sec0045" "titulo" => "Reports of suspected serious adverse reactions" ] 3 => array:2 [ "identificador" => "sec0050" "titulo" => "Frequency of suspected adverse reaction reports by affected MedDRA system organ class" ] 4 => array:2 [ "identificador" => "sec0055" "titulo" => "Observed and expected frequencies by administered doses" ] 5 => array:2 [ "identificador" => "sec0075" "titulo" => "Sensitivity of the CFCV (Centro de Farmacovigilancia de la Comunidad Valenciana) for the detection of rare and serious adverse events: intussusception" ] 6 => array:2 [ "identificador" => "sec0060" "titulo" => "Reports of vaccination errors" ] ] ] 7 => array:2 [ "identificador" => "sec0065" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflicts of interest" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2013-09-10" "fechaAceptado" => "2013-10-14" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec340394" "palabras" => array:3 [ 0 => "Rotavirus vaccines" 1 => "Pharmacovigilance" 2 => "Intussusception" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec340395" "palabras" => array:3 [ 0 => "Vacunas frente a rotavirus" 1 => "Farmacovigilancia" 2 => "Invaginación intestinal" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">The aims of this study were to describe the reports of suspected adverse events due to rotavirus vaccines, and assess the reporting sensitivity for intussusception.</p> <span class="elsevierStyleSectionTitle" id="sect0015">Materials and methods</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Descriptive study performed using the reports of suspected adverse events following rotavirus vaccination in infants aged less than 10 months, as registered in the Pharmacovigilance Centre of the Valencian Community during 2007–2011.</p><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">The reporting rate for intussusception was compared to the intussusception rate in vaccinated infants obtained using the hospital discharge database (CMBD) and the regional vaccine registry.</p> <span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">The adverse event reporting rate was 20 per 100,000 administered doses, with the majority (74%) of the reports being classified as non-serious. Fever, vomiting, and diarrhoea were the adverse events reported more frequently. Two intussusception cases, which occurred within the first seven days post-vaccination, were reported as temporarily associated to vaccination. The reporting sensitivity for intussusception at the Pharmacovigilance Centre in the 1–7 day interval following rotavirus vaccination was 50%.</p> <span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Our results suggest that rotavirus vaccines have, in general, a good safety profile. Intussusception reporting to the Pharmacovigilance Centre shows sensitivity similar to other passive surveillance systems. The intussusception risk should be further investigated using well-designed epidemiological studies, and evaluated in comparison with the well-known benefits provided by these vaccines.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0035">Introducción</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Los objetivos de este estudio fueron describir las notificaciones de sospechas de reacciones adversas relacionadas con las vacunas frente a rotavirus y valorar la sensibilidad de la notificación para invaginación intestinal.</p> <span class="elsevierStyleSectionTitle" id="sect0040">Material y métodos</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Estudio descriptivo, a partir de las notificaciones de sospechas de reacciones adversas relacionadas con las vacunas frente a rotavirus, ocurridas en niños menores de diez meses, registradas en el Centro de Farmacovigilancia de la Comunidad Valenciana durante el periodo 2007-2011.</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Se comparó la tasa de notificación de invaginaciones con la tasa de invaginaciones en vacunados obtenida utilizando la base de datos de altas hospitalarias (CMBD) y el registro nominal de vacunaciones autonómico.</p> <span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">La tasa de notificación de eventos adversos fue de 20 por 100.000 dosis administradas. El 74% de las notificaciones se clasificaron como no graves, siendo la fiebre, los vómitos y la diarrea las sospechas más frecuentes. Dos casos de invaginación, ocurridos en los siete primeros días tras la vacunación, fueron notificados como asociados temporalmente a la vacunación. La sensibilidad de la notificación de invaginación intestinal para el periodo de riesgo de uno a siete días fue del 50%.</p> <span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Los resultados sugieren que las vacunas frente a rotavirus presentan un perfil de seguridad en general adecuado, y que el Centro de Farmacovigilancia de la Comunidad Valenciana, comparado con otros sistemas de vigilancia pasiva, es igualmente sensible para detectar señales de posible asociación con invaginación intestinal. Este riesgo requiere ser investigado con estudios epidemiológicos bien diseñados y comparado con los evidentes beneficios que estas vacunas proporcionan.</p>" ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Please cite this article as: Pérez-Vilar S, Díez-Domingo J, Gomar-Fayos J, Pastor-Villalba E, Sastre-Cantón M, Puig-Barberà J. Vigilancia pasiva de la seguridad postautorización de las vacunas frente a rotavirus: sensibilidad de la notificación de invaginación intestinal. An Pediatr (Barc). 2014;81:77–85.</p>" ] 1 => array:2 [ "etiqueta" => "☆☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Previous presentation in meetings, congresses, or symposiums: summary (part of the original content) accepted for the 7th Vaccine and ISV Congress, October 27th–29th 2013, Sitges, Spain.</p>" ] ] "multimedia" => array:4 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Bines et al.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a>" "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Level 1Surgical and/or radiologic and/or autopsy criteria<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>Air or liquid contrast enema, or the demonstration of an intra-abdominal mass by abdominal ultrasound—with target sign or doughnut sign on transverse section or a pseudo-kidney or sandwich sign on longitudinal section—that is proven to be reduced by hydrostatic enema on postreduction abdominal ultrasound \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Level 2Clinical criteria<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>Two major criteria (evidence of intestinal obstruction, features of intestinal invagination, or evidence of intestinal vascular compromise or venous congestion) or one major criterion and three minor criteria (age <1 year and male sex, abdominal pain, vomiting, lethargy, pallor, hypovolemic shock, plain abdominal radiograph showing an abnormal but non-specific bowel gas pattern) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Level 3Clinical criteria<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>Four or more minor criteria (age < 1 year and male sex, abdominal pain, vomiting, lethargy, pallor, hypovolemic shock, plain abdominal radiograph showing an abnormal but non-specific bowel gas pattern) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Insufficient evidenceIf the evidence available for an event is insufficient because information is missing \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not a caseIf an exclusion criterion is met, or if investigation reveals a negative finding of a necessary criterion for classification in Level 1–3, such an event should be classified as “No, not a case of intussusception”. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab538858.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Classification could be made on the basis of surgical, radiological, or autopsy criteria, and the asterisk denotes the radiological criteria.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Refers to the clinical criteria applied in each case.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Standardised Brighton Collaboration case definition for the diagnosis of acute intussusception in infants and young children.</p>" ] ] 1 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">System-organ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Number of events \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Percentage (%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gastrointestinal disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38.03 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">General disorders and administration site conditions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36.62 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nervous system disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.63 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Skin and subcutaneous tissue disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.22 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infections and infestations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.22 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Respiratory, thoracic, and mediastinal disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.82 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cardiac disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.82 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Blood and lymphatic system disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.41 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Metabolism and nutrition disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.41 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Musculosketal and connective tissue disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.41 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vascular disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.41 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab538857.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Reports of suspected adverse reactions by affected MedDRA system-organ class.</p>" ] ] 2 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">185,654 doses administered in the 2007–2011 period. The expected frequency was calculated as a function of the minimum and maximum incidences found in the clinical trials for both vaccines.</p><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">URTI: upper respiratory tract infection; UK: unknown.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">System-organ class (MedDRA) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adverse event \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Expected incidence<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a></td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Observed frequency<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Expected frequency<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Rotarix<span class="elsevierStyleSup">®</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">RotaTeq<span class="elsevierStyleSup">®</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gastrointestinal disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diarrhoea<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/100a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1857 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Abdominal pain \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">186–1857 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Flatulence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤1857 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Haematochezia<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤1857 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vomiting \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤185,654 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Immune system disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anaphylaxis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UK \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Skin and subcutaneous tissue disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Urticaria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/10,000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/1000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤186 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Angioedema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UK \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dermatitis/rash \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">186–1857 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infections and infestations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">URTI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/100a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤18,565 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Otitis media \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤1857 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nasopharyngitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/1000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤1857 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Respiratory, thoracic, and mediastinal disorders \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bronchospasm \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/10,000a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/1000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤186 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">General disorders and administration site conditions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fever \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/100a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤18,565 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Irritability \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥1/100a<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤18,565 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab538860.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Refers to the 185,654 doses found in the clinical trials of both vaccines.</p>" ] 1 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Diarrhoea includes diarrhoea, haemorrhagic diarrhoea, gastroenteritis, and gastrointestinal disorder.</p>" ] 2 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Haematochezia includes haematochezia, haemorrhagic diarrhoea, and melenas.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Suspected non-intussusception adverse reactions described in the summary of product characteristics of rotavirus vaccines: observed and expected frequencies by administered dose.</p>" ] ] 3 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="4" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Number of intussusception cases in the 2007–2011 period</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Time interval between administration and symptom onset (days) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Centro de Farmacovigilancia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Observational study \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Reporting sensitivity rate (%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1–7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1–21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1–30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1–42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab538859.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Number of intussusception cases reported to the Centro de Farmacovigilancia and number of intussusception cases observed in the observational study: reporting sensitivity for intussusception.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:40 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Withdrawal of rotavirus vaccine, recommendation" ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "MMWR Morb Mortal Wkly Rep" "fecha" => "1999" "volumen" => "48" "paginaInicial" => "1007" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10577495" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Population-based study of rotavirus vaccination and intussusception" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Kramarz" 1 => "E.K. France" 2 => "F. Destefano" 3 => "S.B. Black" 4 => "H. Shinefield" 5 => "J.I. Ward" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2001" "volumen" => "20" "paginaInicial" => "410" "paginaFinal" => "416" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11332666" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intussusception among infants given an oral rotavirus vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.V. Murphy" 1 => "P.M. Gargiullo" 2 => "M.S. Massoudi" 3 => "D.B. Nelson" 4 => "A.O. Jumaan" 5 => "C.A. Okoro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM200102223440804" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2001" "volumen" => "344" "paginaInicial" => "564" "paginaFinal" => "572" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11207352" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Intussusception among recipients of rotavirus vaccine – United States, 1998–1999" ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "MMWR Morb Mortal Wkly Rep" "fecha" => "1999" "volumen" => "48" "paginaInicial" => "577" "paginaFinal" => "581" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10428095" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Rotarix: product information" ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2013" "editorial" => "European Medicines Agency (EMA)" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "RotaTeq. Product information" ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2013" "editorial" => "European Medicines Agency (EMA)" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nota para profesionales sanitarios. Actualización de la información sobre la detección de ADN de circovirus porcino (PCV-1) en la vacuna frente a rotavirus Rotarix<span class="elsevierStyleSup">®</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2010" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nota informativa para profesionales sanitarios. Detección de ADN de circovirus porcino tipo 1 y 2 (PCV-1 y PCV-2) en la vacuna frente a rotavirus RotaTeq<span class="elsevierStyleSup">®</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2010" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nota informativa: Liberación de lotes de la vacuna Rotateq" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2010" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment history. CHMP post-authorisation summary of positive opinion for RotaTeq" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "RotaTeq" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2012" "editorial" => "European Medicines Agency (EMA)" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.M. Patel" 1 => "V.R. López-Collada" 2 => "M.M. Bulhões" 3 => "L.H. de Oliveira" 4 => "A. Bautista Márquez" 5 => "B. Flannery" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1012952" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2011" "volumen" => "364" "paginaInicial" => "2283" "paginaFinal" => "2292" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21675888" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.P. Buttery" 1 => "M.H. Danchin" 2 => "K.J. Lee" 3 => "J.B. Carlin" 4 => "P.B. McIntyre" 5 => "E.J. Elliott" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2011.01.088" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "3061" "paginaFinal" => "3066" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21316503" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Haber" 1 => "M. Patel" 2 => "H.S. Izurieta" 3 => "J. Baggs" 4 => "P. Gargiullo" 5 => "E. Weintraub" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2007-3793" "Revista" => array:6 [ "tituloSerie" => "Pediatrics" "fecha" => "2008" "volumen" => "121" "paginaInicial" => "1206" "paginaFinal" => "1212" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18519491" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.A. Belongia" 1 => "S.A. Irving" 2 => "I.M. Shui" 3 => "M. Kulldorff" 4 => "E. Lewis" 5 => "R. Yin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/INF.0b013e3181af8605" "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2010" "volumen" => "29" "paginaInicial" => "1" "paginaFinal" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19907356" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I.M. Shui" 1 => "J. Baggs" 2 => "M. Patel" 3 => "U.D. Parashar" 4 => "M. Rett" 5 => "E.A. Belongia" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Med Assoc" "fecha" => "2012" "volumen" => "307" "paginaInicial" => "598" "paginaFinal" => "604" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000–2009" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Yen" 1 => "J.E. Tate" 2 => "C.A. Steiner" 3 => "M.M. Cortese" 4 => "M.M. Patel" 5 => "U.D. Parashar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/infdis/jis314" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2012" "volumen" => "206" "paginaInicial" => "41" "paginaFinal" => "48" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22539812" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.S. Zickafoose" 1 => "B.D. Benneyworth" 2 => "M.P. Riebschleger" 3 => "C.M. Espinosa" 4 => "M.M. Davis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archpediatrics.2011.1501" "Revista" => array:6 [ "tituloSerie" => "Arch Pediatr Adolesc Med" "fecha" => "2012" "volumen" => "166" "paginaInicial" => "350" "paginaFinal" => "355" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22213609" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intussusception after rotavirus vaccines reported to US VAERS, 2006–2012" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Haber" 1 => "M. Patel" 2 => "Y. Pan" 3 => "J. Baggs" 4 => "M. Haber" 5 => "O. Museru" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2012-2554" "Revista" => array:6 [ "tituloSerie" => "Pediatrics" "fecha" => "2013" "volumen" => "131" "paginaInicial" => "1042" "paginaFinal" => "1049" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23669521" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "FDA releases final study results of a mini-sentinel postlicensure observational study of rotavirus vaccines and intussusception" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "U.S. Food and Drug Administration (FDA)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2013" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.B. Carlin" 1 => "K.K. Macartney" 2 => "K.J. Lee" 3 => "H.E. Quinn" 4 => "J. Buttery" 5 => "R. Lopert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/cit520" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2013" "volumen" => "57" "paginaInicial" => "1427" "paginaFinal" => "1434" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23964090" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The reporting sensitivities of two passive surveillance systems for vaccine adverse events" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Rosenthal" 1 => "R. Chen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Public Health" "fecha" => "1995" "volumen" => "85" "paginaInicial" => "1706" "paginaFinal" => "1709" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7503351" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.C.P. Weber" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "Advances in inflammation research" "paginaInicial" => "1" "paginaFinal" => "7" "serieFecha" => "1984" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Understanding vaccine safety information from the Vaccine Adverse Event Reporting System" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Varricchio" 1 => "J. Iskander" 2 => "F. Destefano" 3 => "R. Ball" 4 => "R. Pless" 5 => "M.M. Braun" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2004" "volumen" => "23" "paginaInicial" => "287" "paginaFinal" => "294" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15071280" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Notificación electrónica de sospechas de reacciones adversas a medicamentos por los ciudadanos. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2013" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "¿Qué es el Sistema Español de Farmacovigilancia de medicamentos de uso humano?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2013" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Orden 16/2010, de 17 de noviembre, de la Conselleria de Sanidad, por la que se regula la farmacovigilancia de medicamentos de uso humano en la Comunitat Valenciana" ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2010" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sistema de Información Vacunal (SIV)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Pastor-Villalba" 1 => "R. Martín-Ivorra" 2 => "A. Alguacil-Ramos" 3 => "M. Barberá-Catalá" 4 => "C. Pons-Sánchez" 5 => "J. Lluch Rodrigo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2009" "editorial" => "Conselleria de Sanitat. Generalitat Valenciana" "editorialLocalizacion" => "Valencia" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Explotación del registro de altas – CMBD – del Sistema Nacional de Salud. Estadísticos de referencia estatal de GRD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2000–2008" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.E. Bines" 1 => "K.S. Kohl" 2 => "J. Forster" 3 => "L.R. Zanardi" 4 => "R.L. Davis" 5 => "J. Hansen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2004" "volumen" => "22" "paginaInicial" => "569" "paginaFinal" => "574" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14741146" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Información para las notificaciones de sospechas de reacciones adversas a medicamentos por parte de profesionales sanitarios" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2013" ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Medical Dictionary for Regulatory Activities. Available from: <a id="intr0070" class="elsevierStyleInterRef" href="http://www.meddramsso.com/">http://www.meddramsso.com</a> [accessed 03.06.13]." ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "T. Verstraeten" 1 => "A.L. Baughman" 2 => "B. Cadwell" 3 => "L. Zanardi" 4 => "P. Haber" 5 => "R.T. Chen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Epidemiol" "fecha" => "2001" "volumen" => "154" "paginaInicial" => "1006" "paginaFinal" => "1012" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11724716" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Hua" 1 => "H.S. Izurieta" 2 => "B. Slade" 3 => "E.D. Belay" 4 => "P. Haber" 5 => "R. Tiernan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/INF.0b013e3181a66471" "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2009" "volumen" => "28" "paginaInicial" => "943" "paginaFinal" => "947" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19755926" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Loughlin" 1 => "T.C. Mast" 2 => "M.C. Doherty" 3 => "F.T. Wang" 4 => "J. Wong" 5 => "J.D. Seeger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/INF.0b013e3182421390" "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2012" "volumen" => "31" "paginaInicial" => "292" "paginaFinal" => "296" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22173146" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Supraventricular tachycardia in the pediatric primary care setting: age-related presentation, diagnosis, and management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E.A. Schlechte" 1 => "N. Boramanand" 2 => "M. Funk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pedhc.2007.08.013" "Revista" => array:6 [ "tituloSerie" => "J Pediatr Health Care" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "289" "paginaFinal" => "299" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18761230" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluating adverse events after vaccination in the Medicare population" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D.R. Burwen" 1 => "L. La Voie" 2 => "M.M. Braun" 3 => "P. Houck" 4 => "R. Ball" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/pds.1390" "Revista" => array:6 [ "tituloSerie" => "Pharmacoepidemiol Drug Saf" "fecha" => "2007" "volumen" => "16" "paginaInicial" => "753" "paginaFinal" => "761" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17385786" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The risk of immune thrombocytopenic purpura after vaccination in children and adolescents" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.T. O’Leary" 1 => "J.M. Glanz" 2 => "D.L. McClure" 3 => "A. Akhtar" 4 => "M.F. Daley" 5 => "C. Nakasato" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2011-1111" "Revista" => array:7 [ "tituloSerie" => "Pediatrics" "fecha" => "2012" "volumen" => "129" "paginaInicial" => "248" "paginaFinal" => "255" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22232308" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0168827808000652" "estado" => "S300" "issn" => "01688278" ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "WHO position paper-January 2013" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Rotavirus vaccines" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Wkly Epidemiol Rec" "fecha" => "2013" "volumen" => "88" "paginaInicial" => "49" "paginaFinal" => "64" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23424730" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rotavirus vaccination: a concise review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "T. Vesikari" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1469-0691.2012.03981.x" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2012" "volumen" => "18" "numero" => "Suppl. 5" "paginaInicial" => "57" "paginaFinal" => "63" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22882248" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Castilla" 1 => "X. Beristain" 2 => "V. Martínez-Artola" 3 => "A. Navascués" 4 => "M. García Cenoz" 5 => "N. Alvarez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2011.11.071" "Revista" => array:7 [ "tituloSerie" => "Vaccine" "fecha" => "2012" "volumen" => "30" "paginaInicial" => "539" "paginaFinal" => "543" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22122860" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0016508508001807" "estado" => "S300" "issn" => "00165085" ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:3 [ "titulo" => "Acknowledgments" "texto" => "<p id="par0195" class="elsevierStylePara elsevierViewall">Marian Martín-Navarro, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana FISABIO-Public Health and Alexandra C. Pacurari, Erasmus University Medical Center.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/23412879/0000008100000002/v1_201408130145/S2341287914000349/v1_201408130145/en/main.assets" "Apartado" => array:4 [ "identificador" => "26005" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23412879/0000008100000002/v1_201408130145/S2341287914000349/v1_201408130145/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287914000349?idApp=UINPBA00005H" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 11 | 17 |
| 2024 October | 38 | 36 | 74 |
| 2024 September | 45 | 29 | 74 |
| 2024 August | 53 | 60 | 113 |
| 2024 July | 44 | 37 | 81 |
| 2024 June | 53 | 30 | 83 |
| 2024 May | 52 | 35 | 87 |
| 2024 April | 41 | 38 | 79 |
| 2024 March | 51 | 25 | 76 |
| 2024 February | 51 | 30 | 81 |
| 2024 January | 30 | 18 | 48 |
| 2023 December | 56 | 17 | 73 |
| 2023 November | 47 | 22 | 69 |
| 2023 October | 36 | 27 | 63 |
| 2023 September | 29 | 28 | 57 |
| 2023 August | 36 | 19 | 55 |
| 2023 July | 29 | 24 | 53 |
| 2023 June | 34 | 30 | 64 |
| 2023 May | 46 | 24 | 70 |
| 2023 April | 27 | 14 | 41 |
| 2023 March | 61 | 24 | 85 |
| 2023 February | 44 | 19 | 63 |
| 2023 January | 19 | 26 | 45 |
| 2022 December | 63 | 23 | 86 |
| 2022 November | 56 | 44 | 100 |
| 2022 October | 40 | 46 | 86 |
| 2022 September | 35 | 32 | 67 |
| 2022 August | 28 | 63 | 91 |
| 2022 July | 23 | 35 | 58 |
| 2022 June | 28 | 42 | 70 |
| 2022 May | 28 | 38 | 66 |
| 2022 April | 26 | 39 | 65 |
| 2022 March | 45 | 40 | 85 |
| 2022 February | 26 | 25 | 51 |
| 2022 January | 34 | 40 | 74 |
| 2021 December | 27 | 40 | 67 |
| 2021 November | 34 | 36 | 70 |
| 2021 October | 44 | 51 | 95 |
| 2021 September | 28 | 50 | 78 |
| 2021 August | 15 | 42 | 57 |
| 2021 July | 33 | 35 | 68 |
| 2021 June | 23 | 38 | 61 |
| 2021 May | 45 | 26 | 71 |
| 2021 April | 92 | 32 | 124 |
| 2021 March | 40 | 33 | 73 |
| 2021 February | 29 | 17 | 46 |
| 2021 January | 35 | 10 | 45 |
| 2020 December | 31 | 24 | 55 |
| 2020 November | 27 | 22 | 49 |
| 2020 October | 20 | 15 | 35 |
| 2020 September | 32 | 13 | 45 |
| 2020 August | 17 | 8 | 25 |
| 2020 July | 21 | 24 | 45 |
| 2020 June | 23 | 25 | 48 |
| 2020 May | 33 | 20 | 53 |
| 2020 April | 28 | 26 | 54 |
| 2020 March | 41 | 32 | 73 |
| 2020 February | 17 | 23 | 40 |
| 2020 January | 27 | 15 | 42 |
| 2019 December | 49 | 21 | 70 |
| 2019 November | 30 | 9 | 39 |
| 2019 October | 21 | 7 | 28 |
| 2019 September | 28 | 21 | 49 |
| 2019 August | 56 | 15 | 71 |
| 2019 July | 29 | 30 | 59 |
| 2019 June | 26 | 26 | 52 |
| 2019 May | 63 | 17 | 80 |
| 2019 April | 64 | 23 | 87 |
| 2019 March | 18 | 11 | 29 |
| 2019 February | 32 | 22 | 54 |
| 2019 January | 36 | 15 | 51 |
| 2018 December | 30 | 32 | 62 |
| 2018 November | 133 | 23 | 156 |
| 2018 October | 307 | 69 | 376 |
| 2018 September | 133 | 30 | 163 |
| 2018 August | 1 | 0 | 1 |
| 2018 July | 4 | 0 | 4 |
| 2018 June | 5 | 0 | 5 |
| 2018 May | 8 | 0 | 8 |
| 2018 April | 11 | 0 | 11 |
| 2018 March | 17 | 0 | 17 |
| 2018 February | 12 | 0 | 12 |
| 2018 January | 15 | 0 | 15 |
| 2017 December | 16 | 0 | 16 |
| 2017 November | 15 | 0 | 15 |
| 2017 October | 13 | 0 | 13 |
| 2017 September | 12 | 0 | 12 |
| 2017 August | 8 | 0 | 8 |
| 2017 July | 5 | 0 | 5 |
| 2017 June | 28 | 7 | 35 |
| 2017 May | 17 | 9 | 26 |
| 2017 April | 12 | 6 | 18 |
| 2017 March | 7 | 6 | 13 |
| 2017 February | 15 | 3 | 18 |
| 2017 January | 9 | 6 | 15 |
| 2016 December | 25 | 11 | 36 |
| 2016 November | 34 | 4 | 38 |
| 2016 October | 32 | 8 | 40 |
| 2016 September | 19 | 2 | 21 |
| 2016 August | 15 | 3 | 18 |
| 2016 July | 4 | 0 | 4 |
Show all
